The NTAGI hasn’t recommended any vaccine for children below 12. This was because children, the evidence showed, manifested only a mild infection and Omicron being a SARS-CoV-2 variant that induced a high antibody response on infection, a vaccine dose would unlikely be significantly beneficial.
He said that there was no scientific evidence to show that vaccinations would not benefit children because they were being “vaccinated by Omicron”. He added that the CMC study was commissioned before the Omicron wave, but now, following the wave, it had “limited importance”. So the antibody levels in people following an Omicron infection is substantially high and booster doses aren’t really adding to it.” ‘ “The Omicron-led wave, as studies from England have shown, significantly boosted antibody levels. Muliyil, a former principal of the CMC, said. Covishield followed by two Covaxin was most impressive (in levels) and three Covaxin doses gave the least response but that by itself is not the whole story and only shows that the body’s T cells (immunity cells) recognise the virus and produce a response,” Dr. “Every combination, homologous and heterologous, boosted antibody levels. This person too confirmed that antibody numbers from a heterologous booster were higher. A detailed report on the findings of the study is expected in the coming fortnight, according to a person privy to the study who declined to be identified. They presented their findings to the NTAGI as well as the Drugs Controller General of India.Ī heterologous booster is when the third dose is different from the earlier doses. Scientists from the CMC conducted the study on 400 patients, who were given different combinations of Covishield or Covaxin as heterologous or homologous boosters. The NTAGI peruses data on vaccination and is one of the expert scientific bodies that recommends approved vaccines for public administration. So far, India has administered more than 191 crore vaccine doses, with nearly 90% of the adults receiving at least one dose. Mulayil was commenting on headline results from a study conducted by the Christian Medical College, Vellore, and commissioned by the Centre to garner evidence on the way ahead for India’s vaccination policy. A booster dose with a COVID-19 vaccine different from the one used for the first immunisation raised antibody levels more than a booster with the same vaccine.Ī Covishield booster following a two-dose Covaxin immunisation gave the highest antibody response, compared with a Covaxin booster following two Covishield shots, but these levels, on their own, were no guarantee against protection from a future Omicron infection, Jayprakash Muliyil, member of the National Technical Advisory Group on Immunisation (NTAGI), told The Hindu.ĭr.
0 kommentar(er)
